The significance of siglec-15 expression in resectable non-small cell lung cancer

J. Q. Hao; J. Y. Nong; D. Zhao; H. Y. Li; D. Su; L. J. Zhou; Y. J. Dong; C. Zhang; N. Y. Che; S. C. Zhang; J. Z. Lin; J. B. Yang; H. T. Zhang; J. H. Wang

doi:10.4149/neo_2020_200220N161

The significance of siglec-15 expression in resectable non-small cell lung cancer

J. Q. Hao, J. Y. Nong, D. Zhao, H. Y. Li, D. Su, L. J. Zhou, Y. J. Dong, C. Zhang, N. Y. Che, S. C. Zhang, J. Z. Lin, J. B. Yang, H. T. Zhang, J. H. Wang

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Siglec-15 (S15) is another important mechanism of tumor immune escape besides the PD-L1/PD-1 pathway and repre-sents a new kind of immune checkpoint inhibitor. However, the associations of tumor Siglec-15 expression with clinicopath-ological characteristics and outcomes of non-small cell lung cancer (NSCLC), and tumor-infiltrating lymphocytes (TILs) in a tumor microenvironment (TME) have so far been unclear. A total of 324 NSCLC surgical samples on tumor microarray were used in this study for investigating the association of S15 expression with clinicopathological characteristics and overall survival (OS) as well as correlation with TILs using multiplex immunofluorescence staining and PD-L1. Results showed that the expression of S15 in adenocarcinoma was significantly higher than that in squamous cell carcinoma. S15 expression was positively correlated with CD8⁺ T cell density in the stroma. The expression rate of PD-L1 in lung squamous cell carcinoma was higher than that in lung adenocarcinoma. S15 expression was not associated with the prognosis of early NSCLC. The pathological mechanism of the co-expression of S15 and PD-L1 in resectable NSCLC remains to be further studied.

Original language	English (US)
Pages (from-to)	1214-1222
Number of pages	9
Journal	Neoplasma
Volume	67
Issue number	6
DOIs	https://doi.org/10.4149/neo_2020_200220N161
State	Published - 2020

Bibliographical note

Publisher Copyright:
© 2020, AEPress, s.r.o. All rights reserved.

Keywords

Multiplex immunofluorescence staining
NSCLC
Siglec-15
TILs

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.4149/neo_2020_200220N161

OpenUrl availability

Full text

Cite this

@article{4a566e4692774cc49c14a31e6f655a2a,

title = "The significance of siglec-15 expression in resectable non-small cell lung cancer",

abstract = "Siglec-15 (S15) is another important mechanism of tumor immune escape besides the PD-L1/PD-1 pathway and repre-sents a new kind of immune checkpoint inhibitor. However, the associations of tumor Siglec-15 expression with clinicopath-ological characteristics and outcomes of non-small cell lung cancer (NSCLC), and tumor-infiltrating lymphocytes (TILs) in a tumor microenvironment (TME) have so far been unclear. A total of 324 NSCLC surgical samples on tumor microarray were used in this study for investigating the association of S15 expression with clinicopathological characteristics and overall survival (OS) as well as correlation with TILs using multiplex immunofluorescence staining and PD-L1. Results showed that the expression of S15 in adenocarcinoma was significantly higher than that in squamous cell carcinoma. S15 expression was positively correlated with CD8+ T cell density in the stroma. The expression rate of PD-L1 in lung squamous cell carcinoma was higher than that in lung adenocarcinoma. S15 expression was not associated with the prognosis of early NSCLC. The pathological mechanism of the co-expression of S15 and PD-L1 in resectable NSCLC remains to be further studied.",

keywords = "Multiplex immunofluorescence staining, NSCLC, Siglec-15, TILs",

author = "Hao, {J. Q.} and Nong, {J. Y.} and D. Zhao and Li, {H. Y.} and D. Su and Zhou, {L. J.} and Dong, {Y. J.} and C. Zhang and Che, {N. Y.} and Zhang, {S. C.} and Lin, {J. Z.} and Yang, {J. B.} and Zhang, {H. T.} and Wang, {J. H.}",

year = "2020",

doi = "10.4149/neo_2020_200220N161",

language = "English (US)",

volume = "67",

pages = "1214--1222",

journal = "Neoplasma",

issn = "0028-2685",

publisher = "Vydavatel'stvo Slovenkej Akademie Vied/Veda Publishing House of the Slovak Academy of Sciences",

number = "6",

}

TY - JOUR

T1 - The significance of siglec-15 expression in resectable non-small cell lung cancer

AU - Hao, J. Q.

AU - Nong, J. Y.

AU - Zhao, D.

AU - Li, H. Y.

AU - Su, D.

AU - Zhou, L. J.

AU - Dong, Y. J.

AU - Zhang, C.

AU - Che, N. Y.

AU - Zhang, S. C.

AU - Lin, J. Z.

AU - Yang, J. B.

AU - Zhang, H. T.

AU - Wang, J. H.

PY - 2020

Y1 - 2020

N2 - Siglec-15 (S15) is another important mechanism of tumor immune escape besides the PD-L1/PD-1 pathway and repre-sents a new kind of immune checkpoint inhibitor. However, the associations of tumor Siglec-15 expression with clinicopath-ological characteristics and outcomes of non-small cell lung cancer (NSCLC), and tumor-infiltrating lymphocytes (TILs) in a tumor microenvironment (TME) have so far been unclear. A total of 324 NSCLC surgical samples on tumor microarray were used in this study for investigating the association of S15 expression with clinicopathological characteristics and overall survival (OS) as well as correlation with TILs using multiplex immunofluorescence staining and PD-L1. Results showed that the expression of S15 in adenocarcinoma was significantly higher than that in squamous cell carcinoma. S15 expression was positively correlated with CD8+ T cell density in the stroma. The expression rate of PD-L1 in lung squamous cell carcinoma was higher than that in lung adenocarcinoma. S15 expression was not associated with the prognosis of early NSCLC. The pathological mechanism of the co-expression of S15 and PD-L1 in resectable NSCLC remains to be further studied.

AB - Siglec-15 (S15) is another important mechanism of tumor immune escape besides the PD-L1/PD-1 pathway and repre-sents a new kind of immune checkpoint inhibitor. However, the associations of tumor Siglec-15 expression with clinicopath-ological characteristics and outcomes of non-small cell lung cancer (NSCLC), and tumor-infiltrating lymphocytes (TILs) in a tumor microenvironment (TME) have so far been unclear. A total of 324 NSCLC surgical samples on tumor microarray were used in this study for investigating the association of S15 expression with clinicopathological characteristics and overall survival (OS) as well as correlation with TILs using multiplex immunofluorescence staining and PD-L1. Results showed that the expression of S15 in adenocarcinoma was significantly higher than that in squamous cell carcinoma. S15 expression was positively correlated with CD8+ T cell density in the stroma. The expression rate of PD-L1 in lung squamous cell carcinoma was higher than that in lung adenocarcinoma. S15 expression was not associated with the prognosis of early NSCLC. The pathological mechanism of the co-expression of S15 and PD-L1 in resectable NSCLC remains to be further studied.

KW - Multiplex immunofluorescence staining

KW - NSCLC

KW - Siglec-15

KW - TILs

UR - http://www.scopus.com/inward/record.url?scp=85096889004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096889004&partnerID=8YFLogxK

U2 - 10.4149/neo_2020_200220N161

DO - 10.4149/neo_2020_200220N161

M3 - Article

C2 - 32749846

AN - SCOPUS:85096889004

SN - 0028-2685

VL - 67

SP - 1214

EP - 1222

JO - Neoplasma

JF - Neoplasma

IS - 6

ER -

The significance of siglec-15 expression in resectable non-small cell lung cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this